| Followers | 904 |
| Posts | 39687 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Tuesday, November 21, 2023 4:01:27 AM
Stick to your hobby of posting 52 week high and 52 week lows chief.
Recent FBIO News
- Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™ • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million • GlobeNewswire Inc. • 03/30/2026 08:05:00 PM
- Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/25/2026 08:01:00 PM
- Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher • IH Market News • 02/23/2026 03:43:08 PM
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million • GlobeNewswire Inc. • 02/23/2026 02:24:14 PM
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States • GlobeNewswire Inc. • 01/13/2026 12:45:00 PM
- Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission • GlobeNewswire Inc. • 12/15/2025 01:00:00 PM
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology • GlobeNewswire Inc. • 12/10/2025 01:30:00 PM
- Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/14/2025 01:30:00 PM
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 11/12/2025 09:01:00 PM
- Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics • GlobeNewswire Inc. • 11/06/2025 12:00:00 PM
- Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 • GlobeNewswire Inc. • 11/05/2025 01:30:00 PM
- Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference • GlobeNewswire Inc. • 10/24/2025 12:30:18 PM
- Fortress Biotech shares rise after Phase 3 launch of gout treatment • IH Market News • 10/21/2025 02:03:37 PM
- Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout • GlobeNewswire Inc. • 10/21/2025 12:30:37 PM
- Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO • PR Newswire (US) • 10/08/2025 09:45:00 PM
- Journey Medical Corporation to Participate in October 2025 Investor Conferences • GlobeNewswire Inc. • 10/08/2025 12:30:32 PM
- Fortress Biotech shares tumble after FDA rejection of Menkes treatment • IH Market News • 10/01/2025 02:19:46 PM
- Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing • GlobeNewswire Inc. • 10/01/2025 12:05:56 PM
- Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 • GlobeNewswire Inc. • 10/01/2025 12:00:46 PM
- Journey Medical Corporation to Participate in September 2025 Investor Conferences • GlobeNewswire Inc. • 09/03/2025 12:30:57 PM
